1. Introduction {#sec1}
===============

One of the inherited bradycardias that is currently being reported is inherited progressive cardiac conduction disease (IPCCD). Progressive cardiac conduction disease (PCCD) is an unidentified, heterogeneous, life-threatening disease that manifests as progressing fibrosis of the cardiac conduction system \[[@B1]\]. It is characterized by a decreased conduction rate, prolonged PR interval, and widened QRS wave, and it ultimately leads to complete atrioventricular block, syncope, and even sudden cardiac death \[[@B1]\]. Initially, patients present with only a widened QRS wave without a bundle branch block, and later, they develop complete atrioventricular block. Abnormalities in the conduction system may be related to changes in cardiac structure and function \[[@B2]\]. It is currently believed that the etiology of PCCD may be related to genetic factors, valvular disease, cardiomyopathy, and autoimmune disease \[[@B3]\]. PCCD caused by genetic factors was originally called progressive familial heart block (PFHB) \[[@B3]\], and some studies directly used PCCD or IPCCD to refer to progressive conduction system diseases related to genetic factors. It is believed that PCCD is caused by the SCN5A mutation \[[@B4]\], and it may also be correlated with TRPM4 \[[@B5]\], DSP \[[@B6]\], and others. Genetic studies about other kinds of familial bradycardia have been published over the past decade, such as sick sinus syndrome and heart block. However, those studies have still not been summarized, and the clinical significance of the related variants is still unknown.

In 1977, Sanger et al. developed Sanger\'s "chain-termination" or dideoxy technique for nucleic acid sequence testing \[[@B7]\]. The improvement of Sanger sequencing makes DNA sequence testing for complex species available \[[@B8]\]. In the course of the development of next-generation sequencing (NGS), genetic testing becomes quicker, cheaper, and easier \[[@B9]\]. For patients who suffer from inherited cardiac disease, NGS has become a potential choice for the diagnosis, prevention, and treatment of certain diseases \[[@B9]\]. The relationships between inherited ion channel disease, such as long QT syndrome (LQTs) \[[@B10]\] and Brugada syndrome (BrS) \[[@B11]\], inherited cardiomyopathy, such as dilated cardiomyopathy (DCM) \[[@B12]\], hypertrophic cardiomyopathy (HCM) \[[@B13]\], and arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) \[[@B14]\], and variant sequencing have been well studied. However, the role of genetic sequence variants in bradycardia is still under debate.

Evaluation of sequence variants is a complex process. The integrity of both the genome and the protein being translated should be studied. In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recommended an interpretative category of sequence variants and an algorithm for interpretation \[[@B15]\]. The ACMG/AMP classification framework is prominent in the evaluation of the Mendelian system. By evaluating the allele frequency, segregation, de novo, and protein expression, functional studies and other factors, sequencing variants can be scored as pathogenic or benign. The two parallel scoring systems divided mutations into 7 categories ([Table 1](#tab1){ref-type="table"}). Sequence variants were then classified into a five-tier system: "pathogenic," "likely pathogenic," "uncertain significant," "likely benign," and "benign" ([Table 2](#tab2){ref-type="table"}). By using this method, evaluated genomic variants can be quantified. With the development of evaluation methods for sequence variants, a growing number of databases have been developed. InterVar \[[@B16]\] is a tool implementing ACMG/AMP criteria that can automatically analyze sequence variants. LitVar \[[@B17]\] links genomic variants in PubMed and PMC, making functional studies achievable. With those databases, sequence variants can be evaluated properly.

At present, most of the related mutant genes reported in the literature are not analyzed according to the ACMG guidelines. In this article, we summarized and reevaluated pedigree studies of bradycardia published in PubMed from 2008/1/1 to 2019/9/1 using the ACMG/AMP variant classification framework.

2. Materials and Methods {#sec2}
========================

2.1. Database Search {#sec2.1}
--------------------

We searched the PubMed database by using the term "heart block" or "sick sinus syndrome" associated with "pedigree" and "'2008/1/1\'\[PDAT\]: '2019/9/1\'\[PDAT\]" \[We used the term of ((((((((((((((((((((((((Heart Block) OR Block, Heart) OR Blocks, Heart) OR Heart Blocks) OR Auriculo-Ventricular Dissociation) OR Auriculo Ventricular Dissociation) OR Auriculo-Ventricular Dissociations) OR Dissociation, Auriculo-Ventricular) OR Dissociations, Auriculo-Ventricular) OR Atrioventricular Dissociation) OR Atrioventricular Dissociations) OR Dissociation, Atrioventricular) OR Dissociations, Atrioventricular) OR A-V Dissociation) OR A V Dissociation) OR A-V Dissociations) OR Dissociation, A-V) OR Dissociations, A-V)) OR ((((((((((Hereditary bundle branch system defect) OR Heart block, progressive familial, type 1) OR Cardiac conduction defect, progressive) OR Lenegre Lev disease) OR Lenegre-Lev Disease) OR PfhbIa) OR Heart Block, Progressive Familial, Type I) OR Pfhb1a) OR Pfhbi) OR Heart block progressive, familial)) OR ((((Progressive Familial Heart Block, Type II) OR Progressive Familial Heart Block, Type Ia) OR PFHBII) OR PFHB2)) OR (((Progressive Familial Heart Block, Type Ib) OR PFHB1B) OR PFHBIB))) AND (((((((Gene) OR Cistron) OR Cistrons) OR Genetic Materials) OR Genetic Material) OR Material, Genetic) OR Materials, Genetic)) AND ("2008/01/01"\[Date - Publication\]: "3000"\[Date - Publication\])\].

2.2. Study Selection {#sec2.2}
--------------------

The aim of this study was to evaluate genetic studies of bradycardia, in addition to the inclusion criteria and exclusion criteria, as follows:

*Inclusion criterion:* Article published in English or have an abstract written in EnglishPedigree studies with at least one family member with bradycardia (include both sick sinus syndrome and atrioventricular block)

*Exclusion criteria:* Functional studies that demonstrate the main function of the sequence variants that are not focused on bradycardiaStudies that have not demonstrated the specific mutation sites

2.3. Sequence Variants Analyze {#sec2.3}
------------------------------

### 2.3.1. Organization of Relevant Sequence Variants {#sec2.3.1}

After a thorough evaluation of the related articles by two researchers, we gathered basic information about relevant sequence variants. The information included the chromosome position of the sequence variant (version: GRCh38), genomic sequence, protein sequence, dbSNP, gene, clinical manifestations, and so on.

### 2.3.2. Clarification of Sequence Variants {#sec2.3.2}

The variants were named after different versions of genomics, so we used The National Center for Biotechnology Information\'s ClinVar database (<https://www.ncbi.nlm.nih.gov/clinvar/>), Online Mendelian Inheritance in Man (OMIM, <https://www.omim.org>), and The Human Gene Mutation Database (HGMD, <http://www.hgmd.cf.ac.uk/ac/index.php>) to complete detailed information on each variant.

### 2.3.3. Use of the ACMG/AMP Classification Framework to Evaluate {#sec2.3.3}

According to the ACMG/AMP classification framework, we used InterVar (<http://wintervar.wglab.org>) (version: hg38) to evaluate sequence variants directly. With those variants that could not be defined in InterVar, we used The Genome Aggregation Database (gnomAD, <https://console.cloud.google.com/storage/browser/gnomad-public/release/2.0.2/>) to evaluate the allele frequency and LitVar (<https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/LitVar/>) to evaluate whether there were relevant functional studies. Under 0.001 were defined as gnomAD. Based on information gathered in the databases and the ACMG/AMP classification framework (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}), we evaluated related sequence variants and proposed a clinical judgement.

3. Results and Discussion {#sec3}
=========================

We summarized genetic studies published in the PubMed database over 11 years ([Figure 1](#fig1){ref-type="fig"}). A total 1015 articles were enrolled after searching the database. 927 articles were excluded. Finally, 88 articles fit the profile; 99 variants and 34 genes were studied in the current article.

Information in InterVar was gathered to evaluate all the sequence variants, and the relevant evidence for pathogenic and benign criteria was summarized ([Table 3](#tab3){ref-type="table"}). For mutation cannot be defined in InterVar, we used gnomAD and ClinVar to analyze frameshift mutations ([Table 4](#tab4){ref-type="table"}) and large fragment deletions ([Table 5](#tab5){ref-type="table"}). We also gathered information about splicing mutations ([Table 6](#tab6){ref-type="table"}).

We studied 88 articles, including 99 variants and 34 genes, after searching the PubMed database and identified 13 high-priority genes causing familial bradycardia, as follows: ABCC9 \[[@B18]\], ACTN2 \[[@B19]\], CACNA1C \[[@B20], [@B21]\], DES \[[@B22]--[@B27]\], HCN4 \[[@B28]--[@B32]\], KCNQ1 \[[@B33], [@B34]\], KCNH2 \[[@B35]\], LMNA \[[@B36], [@B37]\], MECP2 \[[@B38]\], LAMP2 \[[@B39]\], NPPA \[[@B40]\], SCN5A \[[@B41]--[@B45]\], and TRPM4 \[[@B5], [@B46]--[@B48]\] ([Table 3](#tab3){ref-type="table"}).

We use InterVar to reevaluate APOB, CLCA2 DSG2, GJC1, GLA, GNB2, JPH2, KCNJ3, LDB3, MYBPC3, NKX2-5, NXF5, PDYN, PRKAG2, and TTN, which have been published as pathogenic variants. According to the ACMG/AMP variant classification framework, those genes should be classified into uncertain significance.

For the majority of related genes, the clinical manifestations were not unique. These mutations may lead to bradycardia, arrhythmia, myopathy, and nerve system disease. LMNA mutations may present as AVB and arrhythmia; DES, GJA5, TTN, LAMP2, and MECP2 mutations may present as AVB and myopathy; GNB5 mutation may present as CCD and nerve system disease; HCN4, KCNQ1, PRKAG2, and SCN5A mutations may present as CCD, myopathy, and arrhythmia.

Genetic diagnosis has become an inalienable part of the diagnosis, treatment, and prevention of SCD. Cardiac ion channel disease, closely related to sudden cardiac death (SCD), has been discussed for decades. In contrast, the relationship between bradycardia and genetic factors is still unclear. Syncope and SCD caused by bradycardia are life-threatening diseases. If the relationship between genetic factors and bradycardia is eliminated, SCD could be prevented.

Pedigrees of bradycardia families have been reported for decades. However, those studies are lacking. Some of the studies do not include full information about related sequence variants, and some of the studies do not list the whole family tree. In addition, the methods used to evaluate sequence variants are complex, and different centers have their own experience. It is still doubtful whether those variants are pathogenic. Therefore, ACMG/AMP promotes a guideline for thorough evaluation. By analyzing the allele frequency, segregation, de novo, protein expression, functional studies, and other factors, sequencing variants can be scored into a five-tier system: pathogenic, likely pathogenic, uncertain significant, likely benign, and benign. As accurate as the guideline may be, pathogenicity has been defined as being greater than 90% of pathogenicity \[[@B15]\]. According to the precise classification of pathogenicity, pedigrees of familial bradycardia can be reevaluated. InterVar \[[@B16]\] is a tool implementing ACMG/AMP criteria that can automatically analyze sequence variants. In this article, we used InterVar to summarize 13 high-priority genes, as follows: ABCC9, ACTN2, CACNA1C, DES, HCN4, KCNQ1, KCNH2, LMNA, MECP2, LAMP2, NPPA, SCN5A, and TRPM4 ([Table 3](#tab3){ref-type="table"}). High-throughput sequencing (next-generation sequencing) is quite expensive. In contrast, the gene panel is cheaper and easier to analyze. We recommend that patients with a family history of bradycardia have their clinical manifestations gathered and that related pathogenic genes be highly regarded.

For future reference, multicenter studies on the epidemiology of familial bradycardia should be organized. In addition, detailed information about sequence variants should be addressed in related articles and should be evaluated under the ACMG/AMP classification framework. The relationship between bradycardia and genomic variants remains unknown, and epigenetics and modifier genes should be used to investigate the relationship between genes and diseases.

4. Limitation {#sec4}
=============

We summarized sequence variants published in only the PubMed database. There should be more pathogenic genes studied related to bradycardia.

5. Conclusion and Future Direction {#sec5}
==================================

Only 13 pathogenic genes (99 sequence variants and 34 genes being studied) were identified after using the ACMG/AMP variant classification framework to reevaluate. For future reference, pedigree studies should be fully evaluated before being published.

For patients with familial CCD, 13 high-priority genes are recommended for evaluation. Compared to whole genome sequencing, this will increase the clinical utility of genetic testing.
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###### 

Pathogenic and benign criterion based on ACMG/AMP classification framework.

  Rule                     Category                                                                                                                                              Rule description
  ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Evidence of pathogenic                                                                                                                                                         
  Very strong              PVS1                                                                                                                                                  Null variants which caused loss of function are known to be the mechanism of diseases.
                                                                                                                                                                                 
  Strong                   PS1                                                                                                                                                   Different nucleotide change caused same amino acid change with known pathogenic variants.
  PS2                      De novo (confirmed maternity and paternity) in a patient with no family history and diseases.                                                         
  PS3                      Functional studies supported the effect of related pathogenic variants.                                                                               
  PS4                      Variants\' prevalence significantly increased in affected individuals than controls.                                                                  
                                                                                                                                                                                 
  Moderate                 PM1                                                                                                                                                   Mutation happened in hot spot and known function domain.
  PM2                      Absent (or extremely low) in large population studies.                                                                                                
  PM3                      With recessive disease, detected in *trans* with pathogenic variants.                                                                                 
  PM4                      Variants (in-frame deletions/insertions in a nonrepeat region or stop-loss variants) lead to changes in protein length.                               
  PM5                      Different missense changes at known pathogenic amino acid residue.                                                                                    
  PM6                      De novo (without confirmation of maternity and paternity).                                                                                            
                                                                                                                                                                                 
  Supporting               PP1                                                                                                                                                   Variants known to be the causes affected multiple family members.
  PP2                      Missense variants in a gene that have a low rate of benign missense variation are common mechanism of disease.                                        
  PP3                      Multiple lines of computational evidence support a deleterious effect on the gene or gene products.                                                   
  PP4                      Phenotype specific for disease with single genetic etiology.                                                                                          
  PP5                      Reputable source reports variants as pathogenic.                                                                                                      
                                                                                                                                                                                 
  Evidence of benign                                                                                                                                                             
  Stand-alone              BA1                                                                                                                                                   Allele frequency is \>0.5% base on population database.
                                                                                                                                                                                 
  Strong                   BS1                                                                                                                                                   Allele frequency is greater than expected for disorder.
  BS2                      Recessive heredity being observed in healthy adult.                                                                                                   
  BS3                      Functional studies show no pathogenic effect.                                                                                                         
  BS4                      Without segregation.                                                                                                                                  
                                                                                                                                                                                 
  Supporting               BP1                                                                                                                                                   Missense variant in gene where only loss of function is pathogenic.
  BP2                      Observed in genes with overlapping function without increased disease severity or observed in *cis* with a pathogenic variant.                        
  BP3                      Variants (in-frame deletions/insertions in a nonrepeat region or stop-loss variants) lead to changes in a repetitive region without known function.   
  BP4                      Multiple lines of computational evidence suggest no impact on gene or gene product.                                                                   
  BP5                      Variant found in a case with alternate molecular basis for disease.                                                                                   
  BP6                      Report as benign.                                                                                                                                     
  BP7                      Splicing variant predict an algorithm which predict no impact to the splice consensus sequence.                                                       

###### 

Sequence variant classification.

  ------------------------------------------------------ --------------------------------------------
  Pathogenic                                             1 PVS1+≥1 (PS1‐PS4)
  1 PVS1+≥2 (PM1‐PM6)                                    
  1 PVS1 + 1 (PS1‐PS4) + 1 (PM1‐PM6)                     
  1 PVS1+≥2 (PP1‐PP5)                                    
  ≥2 (PS1-PS4)                                           
  1 (PS1‐PS4)+≥3 (PM1‐PM6)                               
  1 (PS1‐PS4) + 2 (PM1‐PM6)+≥2 (PP1‐PP5)                 
  1 (PS1‐PS4) + 1 (PM1‐PM6)+≥4 (PP1‐PP5)                 
                                                         
  Likely pathogenic                                      1 PVS1 + 1 (PM1‐PM6)
  1 (PS1‐PS4) + 1‐2 (PM1‐PM6)                            
  1 (PS1‐PS4)+≥2 (PP1‐PP5)                               
  ≥3 (PP1‐PP5)                                           
  2 (PM1‐PM6)+≥2 (PP1‐PP5)                               
  1 (PM1‐PM6)+≥4 (PP1‐PP5)                               
                                                         
  Benign                                                 1 BA1
  ≥2 (BS1--BS4)                                          
                                                         
  Likely benign                                          1 (BS1‐BS4) + 1 (BP1‐BP7)
  ≥2 (BP1‐BP7)                                           
                                                         
  Uncertain significant                                  Other criteria shown above have not met OR
  Criterion for benign and pathogenic is contradictory   
  ------------------------------------------------------ --------------------------------------------

OR: odds ratio.

###### 

Evaluate all sequence variants using InterVar database.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Chr   Position    Ref   Alt   Gene      Criterion                      Clinical manifest                                Authors
  ----- ----------- ----- ----- --------- ------------------------------ ------------------------------------------------ -----------------------------------
  12    21882785    G     A     ABCC9     Likely pathogenic              PCCD; SSS                                        Celestino-Soper et al. \[[@B18]\]

  1     236731300   T     C     ACTN2     Likely pathogenic              AVB; AF                                          Girolami et al. \[[@B19]\]

  2     21006288    A     T     APOB      Uncertain significance         PCCD; SSS                                        Celestino-Soper et al. \[[@B18]\]

  12    2567685     G     A     CACNA1C   Likely pathogenic              SSS                                              Zhu et al. \[[@B20]\]

  12    2567694     G     A     CACNA1C   Likely pathogenic              SSS                                              Zhu et al. \[[@B20]\]

  12    2448997     C     T     CACNA1C   Likely pathogenic              PCCD                                             Gao et al. \[[@B21]\]

  12    2504538     G     A     CACNA1C   Pathogenic                     AVB; Timothy syndrome 1 (TS1)                    Sepp et al. \[[@B49]\]

  1     86447519    G     T     CLCA2     Uncertain significance         AVB; PCCD                                        Mao et al. \[[@B50]\]\
                                                                                                                          Tan et al. \[[@B51]\]

  2     219425671   C     A     DES       Uncertain significance         AVB; AF                                          Jurcu et al. \[[@B52]\]

  2     219418500   C     T     DES       Pathogenic                     AVB                                              van Tintelen et al. \[[@B22]\]

  18    31524751    A     G     DSG2      Benign/likely benign           AVB                                              Castellana et al. \[[@B53]\]

  17    44805594    G     T     GJC1      Uncertain significance         AVB                                              Seki et al. \[[@B54]\]

  X     101398869   A     C     GLA       Uncertain significance         HCM; AVB                                         Csanyi et al. \[[@B55]\]

  7     100676751   G     T     GNB2      Uncertain significance         SSS; AVB                                         Stallmeyer et al. \[[@B56]\]

  15    73329719    C     T     HCN4      Pathogenic/likely pathogenic   SSS; LVNC                                        Milano et al. \[[@B28]\]

  15    73343416    A     T     HCN4      Uncertain significance         SSS; AF; LVNC                                    Ishikawa et al. \[[@B31]\]

  15    73329719    C     T     HCN4      Pathogenic/likely pathogenic   SSS                                              Ishikawa et al. \[[@B31]\]

  15    73323745    G     C     HCN4      Likely benign                  SSS                                              Schweizer et al. \[[@B29]\]

  15    73322804    C     A     HCN4      Uncertain significance         AVB                                              Zhou et al. \[[@B57]\]

  20    44160305    A     T     JPH2      Uncertain significance         HCM; AVB                                         Vanninen et al. \[[@B58]\]

  7     150951555   C     A     KCNH2     Pathogenic                     AVB; LQT                                         Priest et al. \[[@B35]\]

  2     155555534   A     C     KCNJ3     Uncertain significance         SSS; AF                                          Yamada et al. \[[@B59]\]

  11    2549192     G     A     KCNQ1     Pathogenic/likely pathogenic   SSS; AF                                          Righi et al. \[[@B34]\]

  X     119589315   C     T     LAMP2     Pathogenic                     AVB; WPW; Danon disease                          Miani et al. \[[@B39]\]

  10    88446830    G     A     LDB3      Benign                         PCCD; SSS                                        Celestino-Soper et al. \[[@B18]\]

  1     156104224   C     T     LMNA      Pathogenic                     AVB; VT; SCD                                     Glocklhofer et al. \[[@B36]\]

  1     156104281   A     G     LMNA      Uncertain significance         AVB; HF                                          Petillo et al. \[[@B60]\]

  1     156106186   G     C     LMNA      Uncertain significance         AVB; HF                                          Petillo et al. \[[@B60]\]

  1     156084953   G     A     LMNA      Pathogenic                     AVB; DCM                                         Wu et al. \[[@B61]\]

  1     156104629   C     T     LMNA      Pathogenic                     AVB; VT; SCD                                     Saga et al. \[[@B62]\]

  1     156104755   T     C     LMNA      Pathogenic/likely pathogenic   AVB; muscular dystrophy; cardiomyopathy          Romeike et al. \[[@B63]\]

  1     156084787   C     T     LMNA      Likely benign                  AVB; AF                                          Saj et al. \[[@B37]\]

  1     156108298   C     T     LMNA      Likely pathogenic              AVB; HCM                                         Francisco et al. \[[@B64]\]

  X     153297719   G     A     MECP2     Pathogenic/likely pathogenic   SSS                                              Shioda et al. \[[@B38]\]

  11    47354497    G     A     MYBPC3    Uncertain significance         AVB                                              Kouakam et al. \[[@B65]\]

  5     172660006   G     A     NKX2-5    Uncertain significance         AVB; AF; DCM                                     Yuan et al. \[[@B66]\]

  5     172661762   C     A     NKX2-5    Uncertain significance         AVB; congenital cardiovascular diseases (CCVD)   Pabst et al. \[[@B67]\]

  5     172660110   G     C     NKX2-5    Uncertain significance         AVB; ASD                                         Xie et al. \[[@B68]\]

  1     11907171    C     T     NPPA      Pathogenic                     SSS; atrial dilatation (AD)                      Disertori et al. \[[@B69]\]

  X     101096287   G     A     NXF5      Uncertain significance         AVB; focal segmental glomerulosclerosis (FSGS)   Esposito et al. \[[@B70]\]

  20    1961153     T     A     PDYN      Uncertain significance         PCCD                                             Su et al. \[[@B71]\]

  20    1961154     C     G     PDYN      Uncertain significance         PCCD                                             Su et al. \[[@B71]\]

  7     151560613   A     G     PRKAG2    Uncertain significance         HCM; AVB                                         Thevenon et al. \[[@B72]\]

  3     38550326    G     T     SCN5A     Uncertain significance         SSS                                              Chen et al. \[[@B73]\]

  3     38603929    G     C     SCN5A     Uncertain significance         AVB                                              Nikulina et al. \[[@B74]\]

  3     38556532    T     C     SCN5A     Uncertain significance         SSS                                              Hothi et al. \[[@B41]\]\
                                                                                                                          Asadi et al. \[[@B75]\]

  3     38550734    A     C     SCN5A     Uncertain significance         SSS                                              Abe et al. \[[@B76]\]

  3     38613790    C     T     SCN5A     Likely pathogenic              SSS                                              Abe et al. \[[@B76]\]

  3     38566426    C     T     SCN5A     Pathogenic                     AVB; DCM                                         Watanabe et al. \[[@B77]\]

  3     38550899    T     A     SCN5A     Uncertain significance         SSS                                              Ishikawa et al. \[[@B31]\]

  3     38581137    G     A     SCN5A     Likely benign                  AVB                                              Hu et al. \[[@B78]\]

  3     38581002    C     T     SCN5A     Uncertain significance         SSS; AFL; AF                                     Moreau et al. \[[@B79]\]

  3     38633207    G     T     SCN5A     Uncertain significance         AVB                                              Thongnak et al. \[[@B80]\]

  3     38613787    G     A     SCN5A     Uncertain significance         PCCD; SSS                                        Baskar et al. \[[@B81]\]\
                                                                                                                          Celestino-Soper et al. \[[@B18]\]

  3     38597787    C     A     SCN5A     Likely pathogenic              SSS; AFL                                         Selly et al. \[[@B82]\]

  3     38630342    T     A     SCN5A     Pathogenic/likely pathogenic   SSS; AFL; VT                                     Holst et al. \[[@B43]\]

  3     38575424    C     A     SCN5A     Uncertain significance         AVB; DCM                                         Ge et al. \[[@B83]\]

  3     38551477    A     T     SCN5A     Likely pathogenic              SSS; AVB                                         Robyns et al. \[[@B84]\]

  3     38560398    G     A     SCN5A     Pathogenic                     AVB                                              Thongnak et al. \[[@B80]\]

  3     38550968    C     A     SCN5A     Uncertain significance         SSS                                              Abe et al. \[[@B76]\]

  19    49196760    G     A     TRPM4     Uncertain significance         PCCD                                             Liu et al. \[[@B47]\]

  19    49157885    G     A     TRPM4     Pathogenic                     PCCD; SSS                                        Kruse et al. \[[@B48]\]

  19    49167950    G     A     TRPM4     Benign                         AVB; VT                                          Bianchi et al. \[[@B46]\]

  19    49196790    A     G     TRPM4     Likely benign                  PCCD                                             Daumy et al. \[[@B5]\]

  19    49202140    A     T     TRPM4     Uncertain significance         AVB; VT                                          Bianchi et al. \[[@B46]\]

  19    49171597    A     G     TRPM4     Uncertain significance         AVB                                              Stallmeyer et al. \[[@B85]\]

  19    49200395    A     G     TRPM4     Pathogenic                     AVB                                              Stallmeyer et al. \[[@B85]\]

  19    49168301    C     T     TRPM4     Pathogenic                     PCCD                                             Liu et al. \[[@B47]\]

  19    49182608    G     A     TRPM4     Uncertain significance         AVB                                              Syam et al. \[[@B86]\]

  19    49188641    G     A     TRPM4     Uncertain significance         AVB                                              Syam et al. \[[@B86]\]

  19    49183108    C     T     TRPM4     Uncertain significance         PCCD                                             Liu et al. \[[@B47]\]

  19    49196597    T     C     TRPM4     Uncertain significance         AVB                                              Stallmeyer et al. \[[@B85]\]

  2     178569522   G     T     TTN       Uncertain significance         SSS                                              Zhu et al. \[[@B20]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Using ClinVar to analysis frameshift mutation.

  Genome AD   Chr                        dbSNP          Gene     Variant                           Functional study   Criterion
  ----------- -------------------------- -------------- -------- --------------------------------- ------------------ ----------------------------------------------
  ---         ---                        ---            ALG13    c.383+2821_383+2822delinsTT       ---                ---
  ---         Chr2:219418955-219418982   rs1114167332   DES      c.493_520del28insGCGT             ---                Pathogenic
  ---         ---                        ---            DSC2     c.2688_2688delinsGAA              ---                ---
  ---         ---                        ---            EXT2     c.1101_1102delAG (E368Kfs^∗^18)   ---                ---
  ---         Chr1:156130627-156130629   rs794728597    LMNA     c.367_369delAAG                   Pathogenic         Likely pathogenic
  ---         ---                        ---            LMNA     c.364_366AAG                      ---                ---
  ---         ---                        ---            LMNA     c.103-105del CTG                  ---                ---
                                                        LMNA     815_818delinsCCAGAC                                  
  ---         ---                        ---            MYL4     c.234delC                         ---                ---
  ---         Chr5:173232761             rs587784067    NKX2.5   c.959delC                         ---                Conflicting interpretations of pathogenicity
  ---         ---                        ---            SCN5A    c.2401_2409delinsTCC              ---                Uncertain significant
  ---         ---                        ---            SCN5A    c.5355_5354delCT                  ---                Uncertain significant
  ---         ---                        ---            SCN5A    c.5368 GNA                        ---                ---
  ---         ---                        ---            SCN5A    c.3142_3153de-l12ins11            ---                ---
                                                        MYH6     delE933                                              
                                                        MYL4     c.234delC                                            

###### 

Using InterVal to analysis large fragment deletion.

  Genome AD   Chr   dbSNP   Gene   Variant                                                                                                                           Functional study
  ----------- ----- ------- ------ --------------------------------------------------------------------------------------------------------------------------------- ------------------
  ---         ---   ---     DES    Deletion-insertion mutation (c.1045-1063 del/G ins), deleting 7 amino acids (Met349-Arg355) and inserting 1 amino acid (Gly349)   ---

###### 

Analyzing splicing mutation.

  Genome AD     Chr               dbSNP         Gene         Variant          Functional study
  ------------- ----------------- ------------- ------------ ---------------- ------------------
  ---           ---               ---           HCN4         c.1737+1G\>T     ---
  ---           Chr:1:156130615   ---           LMNA         c.357-2A\>G      ---
  ---           ---               ---           LMNA         c.357-1G\>T      ---
  ---           ---               ---           LMNA         IVS9-3C\>G       ---
  G = 0.00001   Chr3:38562413     rs397514447   SCN5A        c.3963+2T\>C     ---
  ---           ---               ---           SCN5A        c.1141-2A\>G     ---
  ---           ---               ---           SCN5A        c.-225-820T\>C   ---
  ---           ---               ---           TGF beta 1   c.4246-2A\>G     ---
  ---           ---               ---           MYH6         c.2292+2T\>C     ---
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